References
- Catherino WH, Parrott E, Segars J, et al. Proceedings from the National Institute of Child Health and Human Development Conference on the uterine fibroid research update workshop. Fertil Steril. 2017;96:9–12. Available from: 10.1016/j.bpobgyn.2017.10.008.
- Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519–527.e3.
- Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–176. Available from: http://www.fertstert.org/article/S0015028215019603/fulltext.
- Trefoux Bourdet A, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. Int J Womens Health. 2015;7:321–330. Available from: http://www.dovepress.com/clinical-utility-of-ulipristal-acetate-for-the-treatment-of-uterine-fi-peer-reviewed-article-IJWH.
- Donnez J, Dolmans M. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–686.
- Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–432.
- Donnez J, Tomaszewski J, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.
- Bouchard P, Chabbert-Buffet N, Fauser B. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175–1189. Available from: http://dx.doi.org/10.1016/j.fertnstert.2011.08.021.
- Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018;14(1):107–116. Available from: 10.1080/17425255.2018.1417389.
- Fauser B, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017;12(3):e0173523.
- European Medical Agency. Esmya: new measures to minimise risk of rare but serious liver injury EMA concludes review of medicine for uterine fibroids. 2018.
- Pharmacovigilance Risk Assessment Committee. Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing no new patients should start treatment for the time being. EMA/152535/2018. Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/Press_release/2018/02/WC500243548pdf.
- www.ema.europa.eu/en/documents/overview/ulipristal-acetate-gedeon-richter-epar-medicine-overview_en-0.pdf
- www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-assessment-report_en.pdf
- Longo D, Fauci A, Kasper D, et al. Harrison’s manual of medicine. 18th ed. New York (NY): McGraw-Hill Education; 2013.
- Donnez J, Arriagada P, Marciniak M, et al. Liver safety parameters of Ulipristal Acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225–1232. Available from: 10.1080/14740338.2018.1550070.
- Donnez J, Courtoy GE, Dolmans M. Fibroid management in premenopausal women. Climacteric. 2019;22(1):27–33. Available from: 10.1080/13697137.2018.1549216.
- Rabe T, Saenger N, Ebert AD, et al. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018;2018:1374821.
- Biscione A, Barra V, Bellone E, et al. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis. Gynecol Endocrinol. 2019;1–6. Available from: https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640202.
- Giarrè G, Franchini M, Castellacci E, et al. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study. Gynecol Endocrinol. 2019;1–4. Available from: https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1648419.
- Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110(4):593–595.